Clinical trials: Epirubicin
Triple-negative Breast Cancer
Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients
To compare the efficacy and safety of different adjuvant chemotherapy regimens for low-risk triple-negative breast cancer patients predicted by mRNA-lncRNA model
- Trial name
- NCT06795503
- Testing
- Docetaxel plus cyclophosphamide, Epirubicin, cyclophosphamide plus paclitaxel
- Volunteers
- 1,462 people
- Sponsor
- Fudan University
Breast Cancer
Molecular Triaging of Newly Diagnosed Breast Cancer
The goal of this clinical research study is to learn if using "gene signatures" can be an effective way to decide the best treatment for breast cancer patients.
- Trial name
- NCT01159236
- Testing
- Paclitaxel, Fluorouracil, Doxorubicin
- Sponsor
- M.D. Anderson Cancer Center
HER2-negative Breast Cancer, Neoadjuvant Chemotherapy
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
Recent clinical studies showed that breast cancer patients especially for those with lymph node metastasis may benefit from dose-dense chemotherapy, like adriamycin and cyclophosphamide (AC) q2w×4→ paclitaxel (P) q2w×4.
- Trial name
- NCT04576143
- Testing
- Epirubicin, Cyclophosphamid, Docetaxel
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer
Our study is a prospective, non-inferior, randomized phase II clinical trial, to compare the efficacy and safety profiles of DA versus DAC as adjuvant chemotherapy regimens for early-stage breast cancer patients.
- Trial name
- NCT02838225
- Testing
- Docetaxel, Doxorubicin, Docetaxel, Doxorubicin, Cyclophosphamide
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
T-cell Lymphoma
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
This is a prospective, multicenter, phase III study of Tucidinostat, Azacitidine combined with CHOP versus CHOP in patients with untreated peripheral T-cell lymphoma
- Trial name
- NCT05075460
- Testing
- Tucidinostat, Azacitidine combined with CHOP
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Peking Union Medical College Hospital
Lymphoma
Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003262
- Testing
- bleomycin sulfate, filgrastim, Stanford V regimen
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Breast Cancer
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
The study assesses the efficacy of neoadjuvant treatment with pyrotinib and trastuzumab with chemotherapy, mainly pathological complete response (pCR) rates in the breast and axilla.
- Trial name
- NCT04717531
- Testing
- Pyrotinib, Trastuzumab, Pertuzumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer, Pathological Complete Response
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
Neoadjuvant chemotherapy (NAC) has become the standard therapy for both locally advanced and early-stage breast cancer in recent years for the improvement breast conserving surgery rate and the evaluation of treatment response in…
- Conditions
- Breast Cancer, Pathological Complete Response, Neoadjuvant Chemotherapy
- Trial name
- NCT03349177
- Testing
- Epirubicin, Fluorouracil, Docetaxel
- Volunteers
- 200 people
- Sponsor
- Zhiyong Yu
Breast Cancer
Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer
The purpose of this study is to investigate whether tocotrienol can improve the effect and reduce the side effects of standard chemotherapy before operation for breast cancer.
- Trial name
- NeoToc (NCT02909751)
- Testing
- Epirubicin 90 mg/m2 iv, Cyclophosphamide 600 mg/m2 iv, Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Vejle Hospital
Hepato Cellular Carcinoma (HCC)
Evaluate the Effect of Tirazamine on Primary Liver Cancer.
This Phase I/II trial aims to evaluate the pharmacokinetics, efficacy, and safety of tirapazamine administered via hepatic artery injection followed by TACE in patients with intermediate-stage HCC.
- Trial name
- NCT06848556
- Testing
- tirapazamine, Transarterial Embolization, TACE
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Breast Neoplasms
Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
The purpose of this study is to compare the safety and efficacy of epirubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide in lymph node negative, estrogen receptor (ER) positive, human epithelial growth factor…
- Trial name
- ELEGANT (NCT02549677)
- Testing
- Epirubicin, Docetaxel, cyclophosphamide
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Ruijin Hospital
Breast Neoplasms
Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer
The Danish Breast Cancer Cooperative Group (DBCG) wishes to clarify if recurrence-free and overall life expectancy is longer after docetaxel and cyclophosphamide compared to epirubicin and cyclophosphamide followed by docetaxel…
- Trial name
- READ (NCT00689156)
- Testing
- Epirubicin, cyclophosphamide and docetaxel, docetaxel, cyclophosphamide
- Where
- 13 sites in Denmark
- Volunteers
- 2,015 people
- Sponsor
- Danish Breast Cancer Cooperative Group
Breast Cancer, HR+/HER2- Breast Cancer
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
To explore the efficacy and safety of adebrelimab combined with chemotherapy (epirubicin + cyclophosphamide →docetaxel) neoadjuvant therapy early HR+/HER2- breast cancer with high risk factors after the induction treatment of…
- Trial name
- NCT06470633
- Testing
- Adebrelimab, High Intensity Focused Ultrasoun（HIFU）, Cyclophosphamide
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
HR+/HER2- Breast Cancer
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
Our center plans to conduct a prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of neoadjuvant chemotherapy combined with Anlotinib and Benmelstobart in the treatment of HR+/HER2- breast…
- Trial name
- NCT06874933
- Testing
- Neoadjuvant Chemotherapy in Combination with Anlotinib and Benmelstobart
- Where
- 3 sites in China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Breast Cancer, Paclitaxel
Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer
RATIONALE: Adjuvant chemotherapy has been proven to reduce significantly the risk for relapse and death in women with operable breast cancer.In the North American Inter-Group factorial trial design (CALGB 9741) the concept of…
- Conditions
- Breast Cancer, Paclitaxel, Epirubicin, Cyclophosphamide
- Trial name
- PATEN (NCT01848197)
- Testing
- paclitaxel
- Volunteers
- 1,000 people
- Sponsor
- Taizhou Hospital
Breast Cancer
Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
Triple-negative breast cancer (TNBC) has a relatively bad prognosis whereas there is no standard regimen. Some data showed that platins could improve the efficacy of advance TNBC.
- Trial name
- NCT01150513
- Testing
- EC-T, TP
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Chinese Academy of Medical Sciences
Advanced Small Cell Lung Carcinoma
Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study.
Initial chemosensitivity is known concerning SCLC but relapse is almost systematic, especially at a metastatic stage. Brain metastasis are identified around 40 to 50% during the evolution of the disease.
- Trial name
- EPITAX (NCT06550518)
- Where
- 3 sites in France
- Volunteers
- 29 people
- Sponsor
- University Hospital, Brest
Breast Cancer, Hormone-receptor Positive Breast Cancer
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
This is a Phase II, single-center, double-blind, placebo-controlled, randomized study of Pyrotinib in combination with Doxorubicin/Epirubicin and Cyclophosphamide followed by Docetaxel/nab-Paclitaxel as neoadjuvant therapy for…
- Trial name
- NCT04872985
- Testing
- Pyrotinib, Epirubicin, Doxorubicin Hydrochloride Liposome Injection
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Acute Lymphoblastic Leukemia
Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients
The survival of adult patients with standard-risk acute lymphoblastic leukemia(ALL) need to improve. We want to compare the efficacy of haplo-identical hematopoietic stem cell transplantation (HSCT) with chemotherapy for…
- Trial name
- NCT02042690
- Testing
- Haplo-identical HSCT, Chemotherapy
- Where
- 5 sites in China
- Volunteers
- 131 people
- Sponsor
- Peking University
Peripheral T Cell Lymphoma
Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)
This study evaluates the efficacy and safety of Chidamide plus CHOP regimen for de novo PTCL patients.
- Trial name
- CHOP (NCT03268889)
- Testing
- Chidamide
- Where
- China
- Volunteers
- 39 people
- Sponsor
- The First Affiliated Hospital of Soochow University